CBD-Focused MediPharm Labs Grows Global Cannabis Revenue 83% YoY in Q3 As international Strategy Pays Off

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) reported on Thursday third third-quarter revenue totaled CA$11.4 million ($8.1 million), representing an increase of 17% year-over-year.

The Toronto-based company, which focuses on a pharmaceutical company specializing in precision-based cannabinoids, said quarterly performance is a result of the advancement of the company’s international medical cannabis strategy to increase revenue, while reducing costs and increasing its cash balance.

“Our third quarter results reflect the strength of our international strategy, and the resilience of our differentiated business model,” David Pidduck, CEO of MediPharm Labs, said. “MediPharm is uniquely positioned to serve the most complex and highest value medical cannabis markets worldwide with a range of direct-to-patient, partnership and distribution pathways.”

Q3 2025 Financial Highlights

• International medical cannabis revenue amounted to CA$6.4 million, representing 56% of total revenue, and an 83% year-over-year growth.
• Canadian adult-use and wellness revenue totaled CA$1.8 million, representing a 4% year-over-year increase and 9% sequential growth.
• Gross profit for the quarter was CA$2.6 million, down from CA$3.1 million in the prior year’s period.
• Operating expenses were CA$4.4 million, achieving a decline both year-over-year and sequentially.
• General and administrative expenses decreased 19% year-over-year and 35% versus the prior quarter.
• Adjusted EBITDA came in negative at CA$1.1 million, compared to a CA$743,000 adjusted EBITDA in the same quarter of fiscal 2024, while year-to-date Adjusted EBITDA improved by CA$0.3 million compared to the prior year’s period.
• The company ended the quarter with a cash balance of CA$10.6 million.